TNG Transgene SA

Transgene: Combined General Meeting of May 27, 2020

Regulatory News:

The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 27, 2020) at 10:00 a.m. at the Company's headquarters (400 boulevard Gonthier d'Andernach - Parc d'Innovation - 67400 Illkirch-Graffenstaden) chaired by Philippe Archinard, Chairman and CEO, to approve the company financial statements for the year ended December 31, 2019 and to vote the others resolutions submitted to their approval. As a result of restrictions placed on the movement and gatherings of persons in the context of the COVID-19 pandemic, this General Meeting was held behind closed doors without the physical presence of its shareholders.

At the Combined General Meeting, the shareholders have:

- renewed the mandates of the following Board Members: Philippe Archinard, Benoît Habert, Marie Landel, Maya Saïd and TSGH, Transgene’s majority shareholder, represented by Dominique Takizawa;

- voted the other resolutions submitted, in accordance with the recommendations of the Board of Directors.

Detailed voting results are available on Transgene's website, under the heading Investors > General Meeting.

In the board meeting following the Combined General Meeting, the board of directors:

- confirmed Mr Philippe Archinard, Mrs Marie Landel and Mr Benoît Habert in their respective mandates as Chairman of the Board, Chairman of the Audit Committee and Chairman of the Compensation Committee;

- implemented the reduction of the nominal value from 1.00 euro to 0.50 euro per share. 

EN
27/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

 PRESS RELEASE

Transgene to Present New Immunological Data from Phase I Trial of Indi...

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025 Strasbourg, France, October 3, 2025, 5:45 p.m.  CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will tak...

 PRESS RELEASE

Transgene présente de nouvelles données d’immunologie de la Phase I de...

Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, son vaccin thérapeutique individualisé, au SITC 2025 Strasbourg, France, le 3 octobre 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, présente un poster, à la 40e conférence annuelle de la Société pour l’immunothérapie du cancer (SITC) mettant en avant l’analyse approfondie de la réponse cellulaire T spécifique des néoantigènes issue de l’essai randomisé de Phase I de son vaccin thérapeutiqu...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

ResearchPool Subscriptions

Get the most out of your insights

Get in touch